The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

Completed · Phase 4

Conditions studied: Relapsing Multiple Sclerosis

In brief

This study, REbif® vs Glatiramer acetate in relapsing multiple sclerosis (MS) disease - pharmacogenetic(s) (REGARD-PGx) is a single blood sampling exploratory pharmacogenetic study of the REGARD trial. The aim of this trial is to provide additional data on the factors influencing interferon (IFN) beta response. This is a Phase 4 trial involving subjects who previously participated in the REGARD trial. To address the trial objectives, a single visit follow-up trial will be performed during which a blood sample will be collected.

Key facts

Study ID

NCT01034579

Run by

EMD Serono

People needed

324

Starts

2010-02-01

Expected to finish

2010-11-01

Last updated by the study team

2014-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Was randomized in the REGARD 24735 study
• Is willing and able to comply with the protocol
• Has given written informed consent before performing any trial-related activities

You may not qualify if…

• Is unwilling or unable to participate in the study
• Is already included in the initial REGARD 24735 PGx sub-study

Where it is running

• Please Contact U.S. Medical Information Located in — Rockland, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.